Salud financiera de hoja de balance de Edwards Lifesciences
Salud financiera controles de criterios 6/6
Edwards Lifesciences tiene un patrimonio de accionistas total de $6.7B y una deuda total de $597.0M, lo que sitúa su ratio deuda-patrimonio en 8.9%. Sus activos y pasivos totales son $9.4B y $2.6B respectivamente. El BAIT de Edwards Lifesciences es de $1.7B, por lo que su ratio de cobertura de intereses es de -34.9. Tiene efectivo e inversiones a corto plazo que ascienden a $1.6B.
Información clave
8.3%
Ratio deuda-patrimonio
US$597.20m
Deuda
| Ratio de cobertura de intereses | -31.6x |
| Efectivo | US$1.70b |
| Patrimonio | US$7.19b |
| Total pasivo | US$2.55b |
| Activos totales | US$9.74b |
Actualizaciones recientes sobre salud financiera
Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28
Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Edwards Lifesciences (NYSE:EW) Has A Rock Solid Balance Sheet
Apr 03Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 28Recent updates
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Apr 29Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Apr 15Edwards Lifesciences Corporation's (NYSE:EW) Popularity With Investors Is Clear
Apr 01Edwards Lifesciences' (NYSE:EW) Soft Earnings Don't Show The Whole Picture
Feb 21Edwards Lifesciences: EVOQUE FDA Approval; Critical Care Spin-Off (Rating Maintained)
Feb 14Edwards Lifesciences Corporation (NYSE:EW) Released Earnings Last Week And Analysts Lifted Their Price Target To US$90.47
Feb 08Here's Why Edwards Lifesciences (NYSE:EW) Can Manage Its Debt Responsibly
Jan 28The Returns At Edwards Lifesciences (NYSE:EW) Aren't Growing
Jan 14Edwards Lifesciences: Undervalued With A Substantial Upside Potential
Jan 09Edwards Lifesciences Corporation's (NYSE:EW) Share Price Not Quite Adding Up
Dec 31Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Dec 17Edwards Lifesciences: Sector Derating A Bigger Threat Than Competition Or Slowing Markets
Oct 26Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Oct 23Is Now The Time To Look At Buying Edwards Lifesciences Corporation (NYSE:EW)?
Oct 09Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Sep 26A Look At The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW)
Sep 11Edwards Lifesciences: Rising Dominance In Structural Heart Disease
Aug 21Does Edwards Lifesciences (NYSE:EW) Have A Healthy Balance Sheet?
Jul 16Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Jun 30Edwards Lifesciences (NYSE:EW) Is Reinvesting To Multiply In Value
Jun 15Edwards Lifesciences: Valuation Premium Earned, But Shares Are Not Cheap, Technicals Mixed
Jun 12Are Edwards Lifesciences Corporation (NYSE:EW) Investors Paying Above The Intrinsic Value?
May 31Edwards Lifesciences (NYSE:EW) Has A Rock Solid Balance Sheet
Apr 03What Is Edwards Lifesciences Corporation's (NYSE:EW) Share Price Doing?
Mar 22Investors Shouldn't Overlook The Favourable Returns On Capital At Edwards Lifesciences (NYSE:EW)
Mar 10Calculating The Fair Value Of Edwards Lifesciences Corporation (NYSE:EW)
Feb 26Edwards Lifesciences downgraded to market perform at Raymond James on growth challenges
Feb 06Edwards Lifesciences slips as Piper downgrades on challenging setup
Jan 30Edwards Lifesciences: Short-Term Growth Worries Have Created An Opportunity
Jan 18Edwards Lifesciences: Catalysts For 2023 And Beyond
Dec 30Is Edwards Lifesciences (NYSE:EW) A Risky Investment?
Dec 28Is It Too Late To Consider Buying Edwards Lifesciences Corporation (NYSE:EW)?
Dec 16Edwards Lifesciences CEO Michael Mussallem to retire
Dec 08Edwards Lifesciences (NYSE:EW) Knows How To Allocate Capital
Dec 04Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($4.0B) de EW superan a sus pasivos a corto plazo ($1.2B).
Pasivo a largo plazo: Los activos a corto plazo de EW ($4.0B) superan a sus pasivos a largo plazo ($1.4B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: EW tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de EW ha pasado de 18.9% a 8.9% en los últimos 5 años.
Cobertura de la deuda: La deuda de EW está bien cubierta por el flujo de caja operativo (150.1%).
Cobertura de intereses: EW gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.